Lawson Kroeker Investment Management Inc. NE Sells 18,277 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Lawson Kroeker trimmed its stake in Charles River by 36.6%, selling 18,277 shares and now holds 31,638 shares worth about $6.31 million (≈0.06% of the company), which is its 22nd largest holding and 1.9% of the firm's portfolio.
• Institutional ownership is very high at 98.91%, with major investors like Ameriprise, National Bank of Canada, Norges Bank, Balyasny and Ariel materially increasing positions in recent quarters.
• Analysts hold a consensus rating of “Moderate Buy” with a $206.15 average target amid mixed revisions (Citigroup to $265, Mizuho to $175); Charles River beat Q4 EPS at $2.39 and set FY2026 guidance of 10.70–11.20 EPS.

Lawson Kroeker Investment Management Inc. NE trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 36.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,638 shares of the medical research company's stock after selling 18,277 shares during the quarter. Charles River Laboratories International accounts for 1.9% of Lawson Kroeker Investment Management Inc. NE's portfolio, making the stock its 22nd largest holding. Lawson Kroeker Investment Management Inc. NE owned approximately 0.06% of Charles River Laboratories International worth $6,311,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Ameriprise Financial Inc. lifted its position in shares of Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company's stock worth $96,005,000 after buying an additional 575,039 shares during the period. National Bank of Canada FI grew its position in Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company's stock valued at $148,131,000 after acquiring an additional 511,901 shares during the period. Norges Bank acquired a new position in Charles River Laboratories International during the second quarter worth $76,952,000. Balyasny Asset Management L.P. raised its stake in Charles River Laboratories International by 722.5% during the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company's stock worth $65,885,000 after acquiring an additional 381,432 shares in the last quarter. Finally, Ariel Investments LLC lifted its holdings in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company's stock valued at $214,751,000 after acquiring an additional 314,572 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CRL shares. Mizuho reduced their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a research note on Friday, February 20th. Citigroup lifted their price target on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a "buy" rating in a report on Friday, January 16th. JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a "neutral" rating in a research report on Monday, December 15th. TD Cowen decreased their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, February 20th. Finally, UBS Group raised their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a "neutral" rating in a report on Wednesday, February 25th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $206.15.

Charles River Laboratories International Stock Down 0.1%

NYSE:CRL opened at $173.71 on Friday. The stock's fifty day moving average price is $174.54 and its two-hundred day moving average price is $181.07. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The company has a market cap of $8.57 billion, a price-to-earnings ratio of -58.69, a P/E/G ratio of 2.11 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to analysts' expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business's revenue for the quarter was down .8% on a year-over-year basis. During the same period last year, the firm earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.